Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting
21 sept. 2022 08h34 HE
|
Helsinn Healthcare S.A.
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both clinical trials and real-world settings will be presentedHelsinn...
Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care
08 sept. 2022 08h00 HE
|
Helsinn Healthcare S.A.
Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care Lugano, Switzerland, September 8, 2022 - Helsinn Group...
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
01 sept. 2022 05h08 HE
|
Helsinn Healthcare S.A.
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East* Lugano, Switzerland, September 1, 2022 –...
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer
08 août 2022 04h07 HE
|
Helsinn Healthcare S.A.
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022
02 juin 2022 08h30 HE
|
Helsinn Healthcare S.A.
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022 Lugano, Switzerland, June 02, 2022 - Helsinn Group (“Helsinn”), a fully...
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy
25 mai 2022 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.),...
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
19 mai 2022 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of...
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference
11 mai 2022 07h00 HE
|
Helsinn Healthcare S.A.
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference Lugano, Switzerland, May 11, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with...
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets
04 mai 2022 02h00 HE
|
Helsinn Healthcare S.A.
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* Lugano, Switzerland, and Singapore, 04 May 2022 – Juniper Biologics Pte Ltd , a...
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan
28 mars 2022 04h15 HE
|
Helsinn Healthcare S.A.
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan Tokyo, Japan, and Lugano, Switzerland March 28, 2022 - Taiho...